Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382329 | 1.00 | FOLH1 (0.66) | FOLH1AKR1B1CYP2D6CYP2C9HIF1A | |
| SCHEMBL18095084 | 0.98 | FOLH1 (0.63) | FOLH1AKR1B1CYP2D6CYP2C9HIF1A | |
| SCHEMBL13811862 | 0.93 | FOLH1 (0.58) | FOLH1AKR1B1CYP2D6CYP2C9HIF1A | |
| SCHEMBL19202273 | 0.88 | AKR1B1 (0.58) | FOLH1AKR1B1HIF1A | |
| SCHEMBL70565 | 0.84 | AKR1B1 (0.71) | AKR1B1HIF1ACA2 | |
| SCHEMBL512838 | 0.84 | ATM (0.63) | FOLH1AKR1B1 | |
| SCHEMBL7969088 | 0.84 | AKR1B1 (0.54) | FOLH1AKR1B1HIF1ACA2 | |
| SCHEMBL1706376 | 0.84 | MAOB (0.54) | FOLH1AKR1B1 | |
| SCHEMBL2426602 | 0.84 | AKR1B1 (0.54) | FOLH1AKR1B1MEP1B | |
| SCHEMBL4234448 | 0.84 | FOLH1 (0.61) | FOLH1CYP2D6CYP2C9HIF1AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | claimed |
| WO-2010141883-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-09 | — | — | WO | claimed |
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| CN-115584054-B | Polypropylene beta-crystal nucleating agent composition and application thereof | 中国石油化工股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11897859-B1 | Coumarin compounds as antibacterial agents | King Faisal University (SA) | 2024-02-13 | — | — | US | disclosed |
| EP-4239007-A1 | RESIN, PREPARATION METHOD THEREFOR, RESIN COMPOSITION, AND MOLDED PRODUCT | Lg Chem, Ltd. (KR) | 2023-09-06 | — | — | EP | disclosed |
| EP-4239008-A1 | RESIN, PREPARATION METHOD THEREFOR, RESIN COMPOSITION, AND MOLDED ARTICLE | Lg Chem, Ltd. (KR) | 2023-09-06 | — | — | EP | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230143425-A1 | IMPROVEMENTS RELATED TO SORBENT MEDIA | GENESIS SYSTEMS LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023018307-A1 | RESIN, PREPARATION METHOD THEREFOR, RESIN COMPOSITION, AND MOLDED PRODUCT | 주식회사 엘지화학 | 2023-02-16 | — | — | WO | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| EP-1434579-A1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Tularik Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
| WO-2003030902-A1 | IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS | TULARIK INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-5614532-A | NERVOUS SYSTEM DISORDERS USING N-METHYLASPARTATE ANTAGONIST | MERCK, SHARP & DOHME LTD. (GB) | 1997-03-25 | — | — | US | disclosed |
| EP-0620812-A1 | QUINOLONE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993011115-A2 | QUINOLONE DERIVATIVES AND THEIR USE AS NMDA AND AMPA RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
| EP-0029972-B1 | PREPARATION FOR BRIGHTENING SYNTHETIC FIBRES, PROCESS FOR ITS PREPARATION AND PROCESS FOR OPTICAL BRIGHTENING | CASSELLA Aktiengesellschaft (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4304569-A | Formulation for brightening synthetic fibers and its preparation and use | CASSELLA AG. (DE) | 1981-12-08 | — | — | US | disclosed |
| EP-0029972-A2 | Preparation for brightening synthetic fibres, process for its preparation and process for optical brightening | CASSELLA Aktiengesellschaft (DE) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, MICA, CD74 | FOLH1 3385/4885AKR1B1 1288/4885CYP2D6 2661/4885 |
| US-11897859-B1 | Coumarin compounds as antibacterial agents | MRPS27, VNN1, GANAB | FOLH1 3495/4885AKR1B1 2768/4885CYP2D6 371/4885 |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | FOLH1 2791/4885AKR1B1 521/4885CYP2D6 1399/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | FOLH1 4703/4885AKR1B1 2195/4885CYP2D6 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.